Cryoport Supports Gradalis, Inc.'s Vigil® Platform in Clinical Trials for Autologous Immunotherapies for Multiple Cancers
January 03, 2017 at 07:00 pm IST
Share
Cryoport, Inc. announced that its validated cryogenic logistics solutions are supporting Gradalis, Inc.'s clinical trials to evaluate its investigational Vigil® Engineered Autologous Tumor Cell (EATC) cellular immunotherapy technology for use in cancer treatments. Cryoport is currently supporting Gradalis' phase 2/3 trial for high risk stage III/IV ovarian cancer patients, its randomized Phase 2b trial for Ewing's sarcoma, as well as the pilot combination studies with PD-1/PD-L1 inhibitors, all of which utilize the Vigil bi-shRNA furin and GMCSF. Cryoport's global distribution network will provide the required cryogenic logistics support for multiple participating clinical sites located throughout the U.S. Cryoport's cryogenic cold chain logistics solutions will extend access to patients currently enrolled in the trials.
Cryoport, Inc. is engaged in supply chain solutions for cell and gene therapies. The Companyâs supply chain solutions enable manufacturers, contract manufacturers (CDMOâs), contract research organizations (CROâs), developers, and researchers to carry out their business with certainty. The Company provides a broad array of supply chain solutions for the life sciences industry. Through its platform of critical products and solutions, including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, the Company is enabling the future of medicine worldwide, through its systems, compliant procedures, and approach to supply chain management. Its products and services include Cryoport Express Shippers, Cryoport ELITE Shipper Systems, Cryoport Consulting Services, Cryoport Bioservices, CRYOGENE, CRYOPDP Temperature-controlled Logistics, Cryoport Cryoshuttle, IntegriCell Services, Tec4Med, and others.